Protara Therapeutics (NASDAQ:TARA – Get Free Report) had its price objective increased by Oppenheimer from $26.00 to $30.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Separately, HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics […]
Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report)’s share price rose 1.6% during mid-day trading on Thursday . The company traded as high as $2.02 and last traded at $1.91. Approximately 34,962 shares were traded during trading, an increase of 6% from the average daily volume of 32,991 shares. The stock had previously closed at […]
Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report)’s stock price traded up 1.6% during trading on Thursday . The stock traded as high as $2.02 and last traded at $1.91. 34,962 shares were traded during trading, an increase of 6% from the average session volume of 32,991 shares. The stock had previously closed at $1.88. […]
Protara Therapeutics (NASDAQ:TARA – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends. Profitability This table compares Protara Therapeutics […]
Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 77,700 shares, a drop of 28.5% from the July 15th total of 108,600 shares. Based on an average daily trading volume, of 34,000 […]